Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Literature DB >> 15388473

Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Kim Credito¹, Gengrong Lin, Lois M Ednie, Peter C Appelbaum.

Abstract

The MICs of LBM415, a new peptide diformylase inhibitor, were </=0.06 to 4.0 microg/ml for 258 isolates of Staphylococcus aureus and coagulase-negative staphylococci. LBM415 MICs were similar irrespective of whether the strains were methicillin susceptible or resistant. All strains were also susceptible to vancomycin, linezolid, ranbezolid, daptomycin, oritavancin, and quinupristin-dalfopristin. LBM415 at the MIC was bacteriostatic after 24 h.

Entities: Chemical Species

Mesh：

Substances：

Year: 2004 PMID： 15388473 PMCID： PMC521910 DOI： 10.1128/AAC.48.10.4033-4036.2004

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

23 in total

1. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.

Authors: H W Boucher; C B Wennersten; G M Eliopoulos
Journal: Antimicrob Agents Chemother Date: 2000-08 Impact factor: 5.191

Review 2. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?

Authors: D M Livermore
Journal: J Antimicrob Chemother Date: 2000-09 Impact factor: 5.790

3. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan.

Authors: K Hiramatsu
Journal: Am J Med Date: 1998-05-29 Impact factor: 4.965

4. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

Authors: E Cercenado; F García-Garrote; E Bouza
Journal: J Antimicrob Chemother Date: 2001-01 Impact factor: 5.790

5. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.

Authors: C J Henwood; D M Livermore; A P Johnson; D James; M Warner; A Gardiner
Journal: J Antimicrob Chemother Date: 2000-12 Impact factor: 5.790

6. Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.

Authors: D R Snydman; N V Jacobus; L A McDermott; J R Lonks; J M Boyce
Journal: Antimicrob Agents Chemother Date: 2000-12 Impact factor: 5.191

7. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.

Authors: D L Stevens; L G Smith; J B Bruss; M A McConnell-Martin; S E Duvall; W M Todd; B Hafkin
Journal: Antimicrob Agents Chemother Date: 2000-12 Impact factor: 5.191

8. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.

Authors: F Biavasco; C Vignaroli; R Lupidi; E Manso; B Facinelli; P E Varaldo
Journal: Antimicrob Agents Chemother Date: 1997-10 Impact factor: 5.191

Review 9. Optimal treatment of complicated skin and skin structure infections.

Authors: R L Nichols
Journal: J Antimicrob Chemother Date: 1999-09 Impact factor: 5.790

Review 10. Oxazolidinones: a review.

Authors: D I Diekema; R N Jones
Journal: Drugs Date: 2000-01 Impact factor: 11.431

10 in total

1. Activity of LBM415 compared to those of 11 other agents against Haemophilus species.

Authors: Tatiana Bogdanovich; Kathy A Smith; Catherine Clark; Glenn A Pankuch; Gengrong Lin; Pamela McGhee; Bonifacio Dewasse; Peter C Appelbaum
Journal: Antimicrob Agents Chemother Date: 2006-07 Impact factor: 5.191

2. Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors: Monica Fonseca-Aten; Christine M Salvatore; Asunción Mejías; Ana M Ríos; Susana Chávez-Bueno; Kathy Katz; Ana M Gómez; George H McCracken; R Doug Hardy
Journal: Antimicrob Agents Chemother Date: 2005-10 Impact factor: 5.191

3. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.

Authors: Thomas R Fritsche; Helio S Sader; Roy Cleeland; Ronald N Jones
Journal: Antimicrob Agents Chemother Date: 2005-04 Impact factor: 5.191

4. N-O chemistry for antibiotics: discovery of N-alkyl-N-(pyridin-2-yl)hydroxylamine scaffolds as selective antibacterial agents using nitroso Diels-Alder and ene chemistry.

Authors: Timothy A Wencewicz; Baiyuan Yang; James R Rudloff; Allen G Oliver; Marvin J Miller
Journal: J Med Chem Date: 2011-09-15 Impact factor: 7.446

5. Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas.

Authors: Ken B Waites; Nipun B Reddy; Donna M Crabb; Lynn B Duffy
Journal: Antimicrob Agents Chemother Date: 2005-06 Impact factor: 5.191

9. Potent sub-MIC effect of GSK1322322 and other peptide deformylase inhibitors on in vitro growth of Staphylococcus aureus.

Authors: Deborah Butler; Dongzhao Chen; Karen O'Dwyer; Thomas Lewandowski; Kelly Aubart; Magdalena Zalacain
Journal: Antimicrob Agents Chemother Date: 2013-10-28 Impact factor: 5.191

10. Drug forecast - the peptide deformylase inhibitors as antibacterial agents.

Authors: David R P Guay
Journal: Ther Clin Risk Manag Date: 2007-08 Impact factor: 2.423